Related Experiment Videos
Alpha-blocker therapy for benign prostatic hyperplasia: a comparative review.
S. Larry Goldenberg1, Ernest Ramsey, John Trachtenberg
1Associate Professor of Surgery (Urology), University of British Columbia, Vancouver, British Columbia.
The Canadian Journal of Urology
|April 12, 2001
Summary
Alpha-blockers are now a preferred treatment for benign prostatic hyperplasia (BPH), improving urinary flow and symptoms. While effective, drug selection depends on individual side effect tolerance and administration convenience.
Area of Science:
- Urology
- Pharmacology
Background:
- Pharmacotherapy has replaced surgery as the primary treatment for benign prostatic hyperplasia (BPH).
- Selective alpha1-adrenoreceptor antagonists are effective and widely used for BPH management.
Purpose of the Study:
- To review the efficacy and side effect profiles of commonly prescribed alpha-blockers for BPH.
- To guide clinical decisions in selecting the most appropriate alpha-blocker for individual patients.
Main Methods:
- Review of randomized controlled trials (RCTs) and non-comparative studies.
- Analysis of drug efficacy on mean peak urinary flow and BPH symptom severity.
- Evaluation of reported side effects, including postural hypotension, asthenia, dizziness, and ejaculatory dysfunction.
Main Results:
- Terazosin, doxazosin, and tamsulosin significantly improve urinary flow and BPH symptoms.
- No published trials directly compare the clinical efficacy of these three alpha-blockers.
- Tamsulosin may have a lower incidence of side effects like postural hypotension, asthenia, and dizziness.
- Tamsulosin use is associated with ejaculatory dysfunction in 4.5% of men.
Conclusions:
- The choice between terazosin, doxazosin, and tamsulosin for BPH treatment should be based on patient tolerance for side effects and convenience.
- Further comparative trials are needed to establish definitive differences in clinical efficacy between these alpha-blockers.